<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964534</url>
  </required_header>
  <id_info>
    <org_study_id>AFUGEM D12-2</org_study_id>
    <secondary_id>2013-001463-23</secondary_id>
    <nct_id>NCT01964534</nct_id>
  </id_info>
  <brief_title>Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer</brief_title>
  <acronym>AFUGEM</acronym>
  <official_title>Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine alone or the triplet combination of 5FU, irinotecan and oxaliplatin&#xD;
      (FOLFIRINOX)are the reference 1st line treatment for metastatic pancreatic cancer.&#xD;
&#xD;
      The aim of the AFUGEM study is to evaluate the efficacy of weekly ABI-007 in combination with&#xD;
      weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free&#xD;
      survival in patients with previously untreated metastatic pancreatic cancer.&#xD;
&#xD;
      ABI-007 has been approved for commercialization in 38 countries, including the US, Canada,&#xD;
      the EU, Australia, China, India and Korea for the treatment of women with metastatic breast&#xD;
      cancer. ABI-007 alone and in combination is being evaluated in a number of cancers, including&#xD;
      metastatic melanoma, non-small cell lung cancer, pancreatic cancer, and other solid tumors.&#xD;
      Conditions which are responsive to paclitaxel such as non-hematological solid tumor&#xD;
      malignancies are good clinical candidates for treatment with ABI-007.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 12, 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first.Assessed at 4 months.</time_frame>
    <description>To evaluate the efficacy of weekly ABI-007 in combination with weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free survival in patients with previously untreated metastatic pancreatic cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>Assessed every 2 months during treatment period (- Estimated treatment duration per patient : 6 months).</time_frame>
    <description>Assessed using RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease control (DDC)</measure>
    <time_frame>Assessed up to 30 months after the beginning of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>time interval from inclusion to the date of death from any cause. Assessed up to 30 months after the beginning of the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessed from study entry to 1 month after last study drug administration and up to 30 months after the beginning of the study.</time_frame>
    <description>EORTC QLQ C-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Assessed from study entry to 1 month after last study drug administration, assessed up to 30 months after the beginning of the study</time_frame>
    <description>To evaluate the safety profile of ABI-007 in combination with sLV5FU2 (NCI CTCAE v4.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>ARM 1 ABI-007 + Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 ABI-007 + simplified LV5FU2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-007</intervention_name>
    <description>ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)</description>
    <arm_group_label>ARM 1 ABI-007 + Gemcitabine</arm_group_label>
    <arm_group_label>Arm 2 ABI-007 + simplified LV5FU2</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m² IV /30min (day 1, day 8, day 15)</description>
    <arm_group_label>ARM 1 ABI-007 + Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simplified LV5FU2</intervention_name>
    <description>Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)</description>
    <arm_group_label>Arm 2 ABI-007 + simplified LV5FU2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent, and willing and able to comply with protocol&#xD;
             requirements,&#xD;
&#xD;
          2. Histologically or cytologically proven adenocarcinoma of the pancreas,&#xD;
&#xD;
          3. Metastatic disease confirmed (stage IV),&#xD;
&#xD;
          4. No prior therapy for metastatic disease (in case of previous adjuvant therapy,&#xD;
             interval from end of chemotherapy and relapse must be &gt;12 months),&#xD;
&#xD;
          5. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic&#xD;
             Resonance Imaging) according to RECIST v1.1 guidelines,&#xD;
&#xD;
          6. Age ≥18 years,&#xD;
&#xD;
          7. ECOG Performance status (PS) 0-2,&#xD;
&#xD;
          8. Hematological status: neutrophils (ANC) &gt;1.5x109/L; platelets &gt;100x109/L; haemoglobin&#xD;
             ≥9g/dL,&#xD;
&#xD;
          9. Adequate renal function: serum creatinine level &lt;150µM,&#xD;
&#xD;
         10. Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (≤5xULN in case of liver&#xD;
             metastases)&#xD;
&#xD;
         11. Total bilirubin ≤1.5 x ULN, albumin ≥25g/L&#xD;
&#xD;
         12. Baseline evaluations performed before randomization: clinical and blood evaluations no&#xD;
             more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI,&#xD;
             evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to&#xD;
             randomization,&#xD;
&#xD;
         13. Female patients must be surgically sterile, or be postmenopausal, or must commit to&#xD;
             using reliable and appropriate methods of contraception during the study and during at&#xD;
             least six months after the end of study treatment (when applicable). All female&#xD;
             patients with reproductive potential must have a negative pregnancy test (β HCG)&#xD;
             within 72 hours prior to starting ABI-007 treatment. Breastfeeding is not allowed.&#xD;
             Male patients must agree to use effective contraception in addition to having their&#xD;
             partner use a contraceptive method as well during the trial and during at least six&#xD;
             months after the end of the study treatment,&#xD;
&#xD;
         14. Registration in a national health care system (CMU included for France).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or evidence upon physical examination of CNS metastasis unless adequately&#xD;
             treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard&#xD;
             medical therapy)&#xD;
&#xD;
          2. Local or locally advanced disease (stage I to III),&#xD;
&#xD;
          3. Patient uses warfarin,&#xD;
&#xD;
          4. Uncontrolled hypercalcemia,&#xD;
&#xD;
          5. Pre-existing permanent neuropathy (NCI grade ≥2),&#xD;
&#xD;
          6. Known dihydropyrimidine dehydrogenase (DPD) deficiency,&#xD;
&#xD;
          7. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted&#xD;
             therapy, immunotherapy),&#xD;
&#xD;
          8. Treatment with any other investigational medicinal product within 28 days prior to&#xD;
             study entry,&#xD;
&#xD;
          9. Other serious and uncontrolled non-malignant disease (eg. active infection requiring&#xD;
             systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6&#xD;
             months),&#xD;
&#xD;
         10. Known or historical active infection with HIV, or known active infection untreated&#xD;
             with hepatitis B or hepatitis C.&#xD;
&#xD;
         11. History or active interstitial lung disease (ILD),&#xD;
&#xD;
         12. Other concomitant or previous malignancy, except: i/ adequately treated in-situ&#xD;
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,&#xD;
             iii/ cancer in complete remission for &gt;5 years,&#xD;
&#xD;
         13. Patients with known allergy to any excipient of study drugs,&#xD;
&#xD;
         14. Concomitant administration of live, attenuated virus vaccine such as yellow fever&#xD;
             vaccine and concomitant administration of prophylactic phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste Bachet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital La Pitié-Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Layné</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Réné Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau - CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pancreas</keyword>
  <keyword>GERCOR</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>LV5FU2</keyword>
  <keyword>ABI-007</keyword>
  <keyword>PACLITAXEL ALBUMIN-BOUND PARTICLES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

